Altre lingue Suda Pharmaceuticals Ltd Australian S.E.

Azioni

SUD

AU0000063661

Prezzo di chiusura Australian S.E. Altri mercati azionari			Variaz. 5gg	Var. 1 gen.
- ^AUD	-.--%		-.--%	-.--%

26/03	Arovella Therapeutics riceve impegni fermi per una raccolta di circa 12,5 milioni di dollari australiani	MT
20/03	La collaborazione di Arovella Therapeutics con Imugene su ALA-101-onCARlytics termina; le azioni scendono del 12%.	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Arovella Therapeutics Receives Firm Commitments for About AU$12.5 Million Raise	26/03
Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12%	20/03
Arovella Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	28/02
Arovella Boosts Solid Tumor Pipeline with Novel CAR-iNKT Cell Armouring Tech License	30/01
Arovella Therapeutics Manufactures GMP-Grade Lentiviral Vector for Cancer Therapy Product; Shares Climb 4%	02/01
Arovella Therapeutics Ltd. Announces Change of Company Address	06/12
Arovella Therapeutics Appoints CFO	01/12
Arovella Therapeutics Limited Announces Changes to its Board	01/12
Arovella Therapeutics Limited Announces Executive Changes	01/12
Arovella Therapeutics Secures AU$2 Million Tax Rebate for Fiscal Year 2023	20/11
Australian Shares Flat With Positive Bias Amid Hopes of US Fed Keeping Rates Steady	12/10/23
Arovella Therapeutics Secures License for Tumor Targeting Antibody; Shares Fall 6%	12/10/23
Arovella Therapeutics Limited Announces Retirement of David Simmonds as Non-Executive Director	07/09/23
Arovella Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31/08/23
Arovella Therapeutics Raises AU$2.2 Million From Oversubscribed Share Purchase Plan	11/07/23
Arovella Therapeutics Extends Closing Date of Share Purchase Plan	29/06/23
Arovella Therapeutics, UNC Further Discussions on Enhanced iNKT Cells Performance	26/06/23
Arovella Therapeutics focused on driving ALA-101 into the clinic	08/06/23
Arovella Therapeutics Ends AU$4.1 Million Placement; Launches AU$1 Million Purchase Plan	07/06/23
Arovella Therapeutics progresses patient-focused iNKT vision	08/05/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Suda Pharmaceuticals Ltd Australian S.E.

Azioni

SUD

AU0000063661

Altre lingue

Filtri